Modifying effects of docosahexaenoic acid (DHA) were examined using a medium-term multi-organ carcinogenesis model (DMBDD model). Groups of twenty F344 male rats were treated sequentially with Ndiethylnitrosamine (DEN, i.p.), N-methyl-N-nitrosourea (MNU, i.p.), 1,2-dimethylhydrazine (DMH, s.c.), N-butyl-N-(4hydroxybutyl)nitrosamine (BBN, in drinking water) and dihydroxy-di-N-propylnitrosamine (DHPN, in drinking water) during the first 4 weeks (DMBDD treatment), and then DHA-ethyl ester (DHA-E), DHA-triglyceride (DHA-TG) and/ or tocopherol were administered intragastrically 3 times a week for 31 weeks. Significant inhibition of the development of glutathione S-transferase placental form (GST-P) positive foci was observed in DMBDD treated 30% DHA-TG 404 mg and 128 mg + tocopherols groups and with tocopherol alone; however, this appeared to be due to the tocopherol. DHA treatment did not influence the development of aberrant crypt foci in the large intestine. Histopathologically, the incidences of preneoplastic and neoplastic lesions in other organs were also not increased or decreased by DHA treatment. Thus, the results indicate a lack of chemopreventive and tumor promotion effects of any type of DHA in male rats under the present experimental conditions. (J Toxicol Pathol 2005; 18: [53][54][55][56][57][58][59] 
Introduction
The n-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA) is a major component of fish oil, which has been frequently reported to have chemopreventive potential for colon, mammary gland and pancreas carcinogenesis in rats [1] [2] [3] [4] [5] [6] . For example, DHA was found to suppress aberrant crypt foci (ACF) in the colon induced by azoxymethane (AOM) or 1,2-dimethylhydrazine (DMH) 1, 3 . Furthermore, induction of ACF by the heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo [4,5-b ]pyridine (PhIP), was also inhibited by DHA treatment 4 . Furthermore colon cancer multiplicity was significantly decreased in another study 2, 3 . In the mammary gland, development of tumors was also reduced by a low dose of DHA or eicosapentaenoic acid (EPA) treatment after carcinogen (DMBA) injection 6 ; however, in a clinical trial with familial adenomatous polyposis (FAP) patients a high risk group for colorectal cancer, it was without major influence 7 . The three FAP patients were administered concentrated DHA in fish oil capsules (2.2 g of DHA-TG and 0.6 g eicosapentaenoic acid (EPA) per day) for one or two years. The patients with FAP developed endometrial cancer after 12 months, colon cancer after 24 months and lung cancer after 12 months, respectively 7 .
It is well established that a chemical may act as a tumor inhibitor in one organ and as a promoter in others [8] [9] [10] . It is therefore important to examine modification potential not in a single organ, but rather in the whole body. This requires in vivo experimental models which can detect effects in a wide spectrum of organs, and for this purpose several multi-organ wide-spectrum initiation models have been established [11] [12] [13] [14] . The medium-term approach has clear benefits for the examination of modifying effects of chemicals in multiple organs in a single experiment within a relatively short experimental period [15] [16] [17] and is based on the proven good agreement between the multi-organ carcinogenesis model and long-term experimental results 18 .
The ethyl ester formed by DHA (DHA-E) has been used in many chemoprevention studies [1] [2] [3] [4] [5] [6] , and DHA-TG has been used in a clinical trial study 7 . Therefore, we thought it important to investigate the difference in the modifying effects on carcinogenesis of DHA-E and DHA-TG. In the present study, we investigated the post-initiation-phase modifying activity of DHA-E and DHA-TG at the whole organ level using a rat medium-term multi-organ carcinogenesis model developed in our laboratory 8, 15, 19, 20 . Furthermore, a tocopherol group was included as a comparative control.
Materials and Methods

Animals
Male F344 rats, aged 5 weeks, were obtained from Charles River Japan Inc. (Kanagawa Japan), and housed five to a plastic cage with wood chips for bedding in an air-conditioned room at 22 ± 2°C with a 12-h light: 12-h dark cycle. They were maintained on Oriental MF diet (Oriental Yeast Co., Tokyo, Japan) and tap water ad libitum. The study was started after 1 week of acclimatization. Chemicals N-Diethylnitrosamine (DEN), N-methyl-N-nitrosourea (MNU), 1,2-dimethylhydrazine (DMH) and N-butyl-N-(4hydroxybutyl)nitrosamine (BBN) were obtained from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan) and dihydroxy-di-N-propylnitrosamine (DHPN) was obtained from Nacalai Tesque Co. (Osaka, Japan). The DHA dosing solution was supplied by Nippon Suisan Kaisha, Ltd. (Tokyo, Japan). DHA naturally exists in fish oil as a triglyceride (DHA-TG). DHA-E was chemically synthesized from DHA-TG by removing other fatty acids such as oleic acid and EPA. The contents in the dosing solution used in the present study are shown in Table 1 . They were stored in sealed ampules under anaerobic conditions at -20°C in the dark.
Experimental methods Medium-term multi-organ carcinogenesis study
The experimental protocol is shown in Fig. 1 . The animals were randomly allocated to 8 groups of 10 -20 animals. Those in groups 1 to 5 received the combined carcinogen treatments, consisting of a single i.p. injection of 100 mg/kg body wt. of DEN, four i.p. injections of 20 mg/kg body wt. of MNU, four s.c. injections of 40 mg/kg body wt. of DMH, together with 0.05% BBN for 2 weeks and then 0.1% DHPN for 2 weeks (both given in the drinking water), during the initial 4 week period for multiple initiation (DMBDD treatment) as described previously [21] [22] [23] . Animals in groups 1 to 5 were then given intragastric injections, 1 ml of 128 mg/ml of 97% purity DHA-E, 404 mg/ml of 30% purity DHA-TG, 128 mg/ml of 30% purity DHA-TG, each with 4 mg/ml of tocopherol, or tocopherol alone or distilled water, 3 times a week from 1 week after completion of the DMBDD treatment to the end of the experiment. Animals in groups 6 to 8 were given 128 mg/ml 97% purity DHA-E, 404 mg/ml 30% purity DHA-TG and distilled water as a solvent control without DMBDD treatment from week 5. The treatment times per week and concentration of DHA dosing solution were decided according to a trial study 7 . Animals were weighed once a week in the initial 14 weeks, then once every 2 weeks until the end of the study period, at week 36, w h e n a l l s u r v i v i n g a n i m a l s w e r e s a c r i f i c e d b y exsanguination under ether anesthesia and subjected to complete necropsy.
All experimental procedures were performed in accordance with the in-house guideline for the Care and Use of Laboratory Animals at DIMS Institute of Medical Science.
Aberrant crypt foci assay
Nine or 10 rats for each treatment with DMBDD initiation and 5 rats each without DMBDD were analyzed for colon ACF. The colon was removed, slit open from the anus to the cecum along the longitudinal axis, flattened between sheets of filter paper, and fixed in buffered 10% formalin. Then it was stained with 0.2% methylene blue solution by the procedure of Bird 24 to observed aberrant crypts. The number of aberrant crypt foci per colon, the number of aberrant crypts in each focus, and the location of each focus was determined by microscopy.
Histopathological examination
At necropsy, the brain, liver, kidneys, spleen, heart, lungs, thymus, testes and adrenals were excised and weighed, and the relative percentage organ weights were calculated on the basis of final body weights. These and the other major organs including small and large intestines were fixed in 10% buffered formalin, and routinely processed. Paraffin-embedded sections were stained with hematoxylin and eosin for histopathological examination. Liver slices fixed in 10% buffered formalin were also prepared for quantitative assessment of immunohistochemically demonstrated glutathione S-transferase placental form (GST-P) positive foci, as previously described 25 . GST-P positive foci larger than 0.2 mm in diameter and the total areas of the liver sections examined were quantitated using a video image processor (SPICCA-II, Nippon Avionics, Tokyo, Japan) and the data expressed as numbers and areas (mm 2 ) per unit area of the liver section (cm 2 ).
Statistical analysis
The significance of intergroup differences in numerical data obtained for body and organ weights was assessed using the two-tailed Student's t-test. Insufficient homogeneity of variance was corrected with respect to the degrees of freedom according to the method of Welch. The significance of differe nce s i n t h e i n c i d e n c e s o f histopathological findings between treated and control groups was evaluated using Fisher's exact probability test.
Results
No post-initiation treatment-related clinical signs or mortalities were noted in any of the groups in the current experiment. Eight rats were found dead in the course of study, one in group 1, three in group 2, one in group 3, two in group 4 and one in group 5, and the deaths were all considered to have been caused by the DMBDD treatment.
The average body weights of rats in the DMBDD treated groups were significantly less than in the non-DMBDD initiated groups, throughout the study period. After DMBDD initiation, 30% DHA-TG was associated with retardation of body weight increase from week 7. The body weights in the other DMBDD treated groups were not significantly changed. A significant increase in relative liver weight and a tendency to increase in relative kidney weights were noted in group 2 ( Table 2) .
Quantitative analysis of GST-P positive foci (Fig. 2 ) showed the numbers and areas were significantly decreased by the 404 mg/ml 30% DHA-TG treatment. The numbers were also suppressed by 128 mg/ml 30% DHA-TG and tocopherol alone.
No significant difference was observed in ACF between DHA and/or tocopherol treatment groups and the DMBDD alone group (Table 3) .
Histopathological examination revealed hyperplastic and neoplastic lesions in various organs/tissues in the rats initiated with the five carcinogens (Tables 4, 5 ). However, no DHA treatment-related alteration in their incidences was evident. No proliferative lesions were noted in any of the rats given DHA and tocopherol without DMBDD treatment.
Discussion
The present investigation of the modifying potential of DHA in a rat medium-term multi-organ carcinogenesis model found no modifying effects on lesion development in any organ. Decreases of number and/or area of GST-P positive foci in the liver given 404 mg and 128 mg 30% DHA-TG were demonstrated, but similar results were obtained with tocopherol alone, so the latter was considered responsible, in line with its reported inhibitory potential 26, 27 .
The effect of dietary sardine oil including 28.5% DHA on ra t hep ato carci no genesi s was exa mi ned wit h administration in the initiation and post-initiation period 28 . The sardine oil inhibited the number of DEN-induced GST-P positive foci when administered in the initiation period, but enhanced the area of GST-P positive foci when administered in the post-initiation period. However, in another study, fish oil inhibited AOM-induced GST-P positive foci in the post- initiation stage 29 . These results suggest that the effects of fish oil appear to be dependent on the types of carcinogens. I n t h e p r e s e n t s t u d y , D H A d i d n o t e n h a n c e hepatocarcinogenesis initiated with five carcinogens. Some previous studies indicated the chemopreventive effect of DHA on colon 1-4 , mammary glands 6 and pancreas carcinogenesis 5 in rats. DHA exerted significant inhibitory effects on implanted tumor growth and metastasis to the lungs in a subcutaneously implanted and highly metastatic colon carcinoma model 30 . However, no chemoprevention was observed for rat colon and other organ carcinogenesis with DHA treatment in the present study. The reason for the discrepancy with the many previous studies which showed chemopreventive effects on colon carcinogenesis and ACF development [1] [2] [3] [4] 27, 31, 32 , may be due to the different number of treatment times per week. DHA was injected five times a week or administered in diet continuously in the other chemopreventive studies, but injected three times a week in this study, according to the clinical trial study 7 .
In the multi-organ model (DMBDD model) 20,21,23,33 incidences of colon tumor development have been reported to range from 10 to 80%, therefore the figure of 10% achieved in the present study was relatively low. Thus, one reason for the lack of obvious influence of DHA could have been due to weak initiation. R e c e n t l y , d i f f e r e n t r e s u l t s r e g a r d i n g t h e chemopreventive effect of DHA-E in diet using the same model were published by an other group 33 . They showed an inhibitory effect on carcinogenesis in the small intestine, large intestine and lung by DHA. They used synthetic diet (modified AIN-93) as basal diet for the experiment, but we used a conventional diet (Oriental MF), this may have been the cause of the different results.
DHA has been reported as an useful chemopreventive agent in many rodent studies [1] [2] [3] [4] [5] [6] . However, in a long-term trial using concentrated DHA in fish oil capsules containing about 30% DHA in triglyceride form, for patients in a highrisk group for colorectal cancer, three patients with FAP developed cancers, one endometrial, one colon and one lung 7 . During the trial, no marked increase or decrease in the number of polyps was observed.
In the present experiment, no promotion activity of either DHA-E or DHA-TG was found in any organ including the large intestine. The reason for the tumor development seen in the clinical trial study with DHA-TG treatment could not therefore be clarified in the present study.
